Abstract
Chronic pseudomonal bronchopulmonary infections in cystic fibrosis patients are frequently controlled with inhaled antibiotics. Dry-powder inhalable antibiotics are an attractive alternative to nebulized medications. We produced and evaluated microparticles composed of dipalmitoylphosphatidylcholine, albumin, and lactose as a model system for intrapulmonary delivery of ceftazidime, ciprofloxacin, and several combinations of the two, none of which is presently available for inhalation. Microparticles containing one or both antibiotics were prepared by spray-drying. Their Anderson cascade impactor deposition profiles showed 10–30% fine particle fractions of the nominal dose. Microparticles containing varying amounts of each antibiotic showed statistically different deposition profiles. Aerodynamics and deposition of microparticles co-encapsulating both antibiotics were similar to those of single-drug microparticles with the same proportion of ciprofloxacin alone. The antipseudomonal activities of microparticles co-encapsulating half of the 50% effective concentration (EC50) of both ceftazidime and ciprofloxacin (5 mg of particles containing 5% ceftazidime and 10% ciprofloxacin) were at least additive compared to particles containing the EC50 of each antibiotic separately (5 mg of particles containing 10% ceftazidime or 5 mg of particles containing 20% ciprofloxacin). Co-encapsulation of the antibiotics in microparticles ensures co-deposition at desired ratios, improves the particles’ aerodynamics and fine particle fraction, as compared to microparticles with equivalent amounts of ceftazidime alone, and achieves additive antipseudomonal activity.
Similar content being viewed by others
References
A. R. Penketh, A. Wise, M. B. Mearns, M. E. Hodson, and J. C. Batten. Cystic fibrosis in adolescents and adults. Thorax. 42(7):526–532 (1987).
M. I. Gomez, and A. Prince. Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. Curr Opin Pharmacol (2007).
M. E. Hodson, and C. G. Gallagher. New clinical evidence from the European tobramycin trial in cystic fibrosis. J. Cyst. Fibros. 1(Suppl 2):199–202 (2002).
B. W. Ramsey, M. S. Pepe, J. M. Quan, K. L. Otto, A. B. Montgomery, J. Williams-Warren, K. M. Vasiljev, D. Borowitz, C. M. Bowman, B. C. Marshall et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 340(1):23–30 (1999).
M. E. Hodson. Antibiotic treatment. Aerosol therapy. Chest. 94(2 Suppl):156S–162S (1988).
P. W. Campbell 3rd, and L. Saiman. Use of aerosolized antibiotics in patients with cystic fibrosis. Chest. 116(3):775–788 (1999).
L. Weathers, D. Riggs, M. Santeiro, and R. E. Weibley. Aerosolized vancomycin for treatment of airway colonization by methicillin-resistant Staphylococcus aureus. Pediatr. Infect. Dis. J. 9(3):220–221 (1990).
L. Máiz, R. Cantón, N. Mir, F. Baquero, and H. Escobar. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatric. Pulmonology. 26(4):287–289 (1998).
J. D. Gradon, E. H. Wu, and L. I. Lutwick. Aerosolized vancomycin therapy facilitating nursing home placement. Ann. Pharmacother. 26(2):209–210 (1992).
B. Laube. Aerosol delivery systems. In G. Loughlin, and H. Eigen (eds.), Respiratory Disease in Children: Diagnosis and Management, Williams and Wilkins, Baltimore, MD, 1994, pp. 721–729.
R. S. Bernard, and L. L. Cohen. Increasing adherence to cystic fibrosis treatment: a systematic review of behavioral techniques. Pediatr. Pulmonol. 37(1):8–16 (2004).
M. A. Wall, A. B. Terry, J. Eisenberg, M. McNamara, and R. Cohen. Inhaled antibiotics in cystic fibrosis. Lancet. 1(8337):1325 (1983).
R. L. Elmore, M. E. Contois, J. Kelly, A. Noe, and A. Poirier. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin. Ther. 18(2):246–255 (1996).
C. G. Prober, P. D. Walson, and J. Jones. Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs. Pediatrics. 106(6):E89 (2000).
C. Bosquillon, C. Lombry, V. Preat, and R. Vanbever. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control. Release. 70(3):329–339 (2001).
C. Bosquillon, P. G. Rouxhet, F. Ahimou, D. Simon, C. Culot, V. Preat, and R. Vanbever. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J. Control. Release. 99(3):357–367 (2004).
R. E. Dostal, J. P. Seale, and B. J. Yan. Resistance to ciprofloxacin of respiratory pathogens in patients with cystic fibrosis. Med. J. Aust. 156(1):20–24 (1992).
J. Watkins, J. Francis, and J. A. Kuzemko. Does monotherapy of pulmonary infections in cystic fibrosis lead to early development of resistant strains of Pseudomonas aeruginosa? Scand. J. Gastroenterol. Suppl. 143:81–85 (1988).
S. M. Cheer, J. Waugh, and S. Noble. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs. 63(22):2501–2520 (2003).
A. L. Smith, B. W. Ramsey, D. L. Hedges, B. Hack, J. Williams-Warren, A. Weber, E. J. Gore, and G. J. Redding. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr. Pulmonol. 7(4):265–271 (1989).
J. L. Burns, J. M. Van Dalfsen, R. M. Shawar, K. L. Otto, R. L. Garber, J. M. Quan, A. B. Montgomery, G. M. Albers, B. W. Ramsey, and A. L. Smith. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. 179(5):1190–1196 (1999).
D. N. Fish, M. K. Choi, and R. Jung. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J. Antimicrob. Chemother. 50(6):1045–1049 (2002).
S. L. Pendland, C. R. Messick, and R. Jung. In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa. Diagn. Microbiol. Infect. Dis. 42(1):75–78 (2002).
D. A. Edwards, A. Ben-Jebria, and R. Langer. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J. Appl. Physiol. 85(2):379–385 (1998).
D. S. Kohane, M. Lipp, R. C. Kinney, N. Lotan, and R. Langer. Sciatic nerve blockade with lipid–protein–sugar particles containing bupivacaine. Pharm. Res. 17(10):1243–1249 (2000).
R. Vanbever, J. D. Mintzes, J. Wang, J. Nice, D. Chen, R. Batycky, R. Langer, and D. A. Edwards. Formulation and physical characterization of large porous particles for inhalation. Pharm. Res. V16(11):1735 (1999).
D. S. Kohane, S. E. Smith, D. N. Louis, G. Colombo, P. Ghoroghchian, N. G. M. Hunfeld, C. B. Berde, and R. Langer. Prolonged duration local anesthesia from tetrodotoxin-enhanced local anesthetic microspheres. Pain. 104(1,2):415–421 (2003).
J. Castillo, J. Curley, J. Hotz, M. Uezono, J. Tigner, M. Chasin, R. Wilder, R. Langer, and C. Berde. Glucocorticoids prolong rat sciatic nerve blockade in vivo from bupivacaine microspheres. Anesthesiology. 85(5):1157–1166 (1996).
G. Colombo, R. Padera, R. Langer, and D. Kohane. Prolonged duration local anesthesia with lipid–protein–sugar particles containing bupivacaine and dexamethasone. J. Biomed. Mater. Res. A. 75(2):458–464 (2005).
J. P. Mitchell, and M. W. Nagel. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J. Aerosol. Med. 16(4):341–377 (2003).
J. M. Goldman, S. M. Bayston, S. O’Connor, and R. E. Meigh. Inhaled micronised gentamicin powder: a new delivery system. Thorax. 45(12):939–940 (1990).
N. R. Crowther Labiris, A. M. Holbrook, H. Chrystyn, S. M. Macleod, and M. T. Newhouse. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study. Am. J. Respir. Crit. Care Med. 160(5 Pt 1):1711–1716 (1999).
M. T. Newhouse, P. H. Hirst, S. P. Duddu, Y. H. Walter, T. E. Tarara, A. R. Clark, and J. G. Weers. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest. 124(1):360–366 (2003).
H. Adi, P. M. Young, H. K. Chan, P. Stewart, H. Agus, and D. Traini. Cospray dried antibiotics for dry powder lung delivery. J Pharm Sci. (2007).
Gentamicin. Micromedex® Healthcare Series. Thomson Micromedex
Ciprofloxacin. Micromedex® Healthcare Series. Thomson Micromedex
Ceftazidime. Micromedex® Healthcare Series. Thomson Micromedex
ACKNOWLEDGMENT
We would like to express our gratitude to Henry Dorkin, MD for helpful insights. This work was supported by Cystic Fibrosis Foundation Research and Clinical Fellowship grant (TSIFAN02B0) to MDT and NIH GM073626 to DSK.
Author information
Authors and Affiliations
Corresponding author
Additional information
Michael D. Tsifansky and Yoon Yeo contributed equally.
Rights and permissions
About this article
Cite this article
Tsifansky, M.D., Yeo, Y., Evgenov, O.V. et al. Microparticles for Inhalational Delivery of Antipseudomonal Antibiotics. AAPS J 10, 254–260 (2008). https://doi.org/10.1208/s12248-008-9033-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-008-9033-8